Back

Clifford Chance advises Medlive Technology’s US$5.4 million Hong Kong IPO

Established in 2013, Medlive Technology is one of the largest online platforms for medical professionals (physicians, pharmaceutical and medical device companies, hospitals) and patients in China. Medlive Technology provides its participants with a wide spectrum of solutions, including digital healthcare marketing services, patient recruitment service for clinical trials, real-world studies (RWS) solutions, latest clinical references, AI-enabled patient management services and electronic data capture (EDC) system for automated data collection and management.

Partners Christine Xu and Fang Liu co-led the deal with support from senior associates Gehuan Liu, Queenie Tong, Qingqing Bu, Emma Bao and trainee Yumeng Fan.

Christine said, “The successful IPO of Medlive Technology indicates that the demand for initial public offerings in Hong Kong will continue to grow especially in the healthcare and TMT sectors. We are honoured to have supported Medlive Technology in achieving a historic milestone in its development.”

The firm’s Greater China IPO practice regularly advises on IPOs in the healthcare sector, including Ping An Good DoctorSciClone Pharmaceuticals and Hygeia Healthcare. The firm has also advised on the IPOs of early-stage biotech companies such as Zylox-Tonbridge Medical TechnologyHarbour BioMed and Ascentage Pharma.

LEGAL DESIRE NEWSLETTER

Where the legal industry reads first.

Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.

No spam. Unsubscribe anytime.

From Legal Desire

Is your firm the one being cited, or the one being skipped?

We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.

Legal Desire Press
https://legaldesire.com/about-us/
Our editorial team that covers judgments, deals, law firm updates, careers and policy across the globe. Coverage is editorially independent; sponsored posts are labeled Partner Content.

Leave a Reply

Your email address will not be published. Required fields are marked *